Bulletin
Investor Alert

ObsEva S.A.

NAS: OBSV

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 23, 2020, 7:10 p.m.

/zigman2/quotes/208216166/composite

$

2.61

Change

+0.0050 +0.19%

Volume

Volume 1,611

Quotes are delayed by 20 min

/zigman2/quotes/208216166/composite

Today's close

$ 2.77

$ 2.61

Change

-0.17 -5.96%

Day low

Day high

$2.58

$2.80

Open

52 week low

52 week high

$1.63

$9.62

Open

Company Description

ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November ...

ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.

Valuation

Price to Book Ratio

3.14

Total Debt to Enterprise Value

0.22

Efficiency

Income Per Employee

-2,171,457.00

Liquidity

Current Ratio

3.84

Quick Ratio

3.84

Cash Ratio

3.56

Profitability

Return on Assets

-80.17

Return on Equity

-111.08

Return on Total Capital

-96.09

Return on Invested Capital

-97.86

Capital Structure

Total Debt to Total Equity

55.31

Total Debt to Total Capital

35.61

Total Debt to Total Assets

26.05

Long-Term Debt to Equity

54.05

Long-Term Debt to Total Capital

34.80

Officers and Executives

Name Age Officer Since Title
Dr. Ernest Loumaye 66 2012 Chief Executive & Medical Officer
Mr. Fabien de Ladonchamps 40 2013 Chief Financial Officer
Dr. Elizabeth Ijeoma Onyemelukwe Garner 51 2019 Chief Medical Officer
Dr. Jean-Pierre Gotteland 54 2015 Chief Scientific Officer
Dr. Elke Bestel 52 2015 VP, Head-Drug Safety & Pharmacovigilance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/obsv

MarketWatch News on OBSV

  1. ObsEva downgraded to neutral from overweight at JPMorgan, price target slashed to $5 from $18

    9:24 a.m. July 7, 2020

    - Tonya Garcia

  2. ObsEva price target lowered to $5 from $7 at SVBLeerink, outperform stock rating maintained

    7:51 a.m. July 7, 2020

    - Tonya Garcia

  3. ObsEva shares rise on new data about fibroid treatment

    9:19 a.m. Dec. 9, 2019

    - Jaimy Lee

  4. ObsEva stock price target cut to $18 from $27 at SVB Leerink

    7:37 a.m. Nov. 8, 2019

    - Tomi Kilgore

  5. A Small Biotech With a Promising Pipeline

    9:29 p.m. Sept. 14, 2018

    - Barron's Online

  6. ObsEva started at overweight with $29 stock price target at J.P. Morgan

    7:13 a.m. Sept. 13, 2018

    - Tomi Kilgore

  7. Consumer Confidence Seen to Be Waning

    4:33 a.m. July 22, 2017

    - Barron's Online

/news/nonmarketwatch/company/us/obsv

Other News on OBSV

  1. SAN, JKS among premarket gainers

    8:13 a.m. Sept. 4, 2020

    - Seeking Alpha

  2. TSLA, MRNA among premarket gainers

    8:19 a.m. Aug. 12, 2020

    - Seeking Alpha

  3. NVAX, LVGO among premarket gainers

    8:18 a.m. July 7, 2020

    - Seeking Alpha

  4. PSXP, KNDI, GNUS and SOLO among midday movers

    12:45 p.m. July 6, 2020

    - Seeking Alpha

  5. ObsEva down 42% on late-stage linzagolix data

    11:29 a.m. July 6, 2020

    - Seeking Alpha

  6. ObsEva Has A Promising Candidate For An Unmet Need

    8:00 a.m. May 13, 2020

    - Seeking Alpha

  7. PTLA, TGTX, NCLH and HTZ among midday movers

    12:42 p.m. May 5, 2020

    - Seeking Alpha

  8. How ObsEva (OBSV) Stock Stands Out in a Strong Industry

    8:45 a.m. April 23, 2020

    - Zacks.com

  9. ObsEva up 10% after hours on long-term linzagolix data

    4:57 p.m. April 22, 2020

    - Seeking Alpha

  10. New interim CFO at ObsEva

    7:24 a.m. April 6, 2020

    - Seeking Alpha

  11. ObsEva updates on clinical programs amid Covid-19

    7:00 a.m. March 23, 2020

    - Seeking Alpha

  12. INO, OPK, OAS and TRXC among midday movers

    1:39 p.m. March 6, 2020

    - Seeking Alpha

  13. ObsEva and Selecta Bio up premarket on bullish ratings

    8:04 a.m. Jan. 29, 2020

    - Seeking Alpha

  14. Loading more headlines...

At a Glance

ObsEva SA

Chemin des Aulx, 12

Plan-les-Ouates

Geneva, Geneve (Geneva) 1228

Phone

41 225523840

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

N/A

Net Income

$-108.79M

Employees

50.00

/news/pressrelease/company/us/obsv

Press Releases on OBSV

  1. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.